Search Results

JenaValve’s ALIGN-AR Pivotal Trial Results for Trilogy THV System Are Published

March 28, 2024—JenaValve Technology, Inc. announced the publication of results from the ALIGN-AR pivotal trial, which is a prospective, multicenter study evaluating the use of the company’s Trilogy transcatheter heart valve (THV) system in high-risk patients with symptomatic moderate-to-severe or severe aortic regurgitation (AR).

Edwards Acquires JenaValve and Endotronix

July 25, 2024—Edwards Lifesciences announced it has entered into an agreement to acquire JenaValve Technology, which is focused on transcatheter treatment of aortic regurgitation (AR).

JenaValve’s Trilogy THV System Assessed in ALIGN-AR Pivotal Trial

October 24, 2023—JenaValve Technology, Inc. announced results from the ALIGN-AR pivotal trial of the company’s Trilogy transcatheter heart valve (THV) system in high-risk patients with symptomatic, severe aortic regurgitation (AR).

ESC/EACTS Valvular Heart Disease Guidelines Address TAVR for Aortic Regurgitation

September 12, 2025—Updated guidelines on valvular heart disease have been published by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).